June 23, 2015
Phase I Trial analyses shows safety and positive immune response data
SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial.
Read More
June 3, 2015
SEATTLE, June 2, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a clinical stage cancer immunotherapy company, and its institutional investors have reached an agreement whereby the institutional investors will have the option to exercise their short term warrants to provide the Company up to $4.93M in near term funding, pending closing conditions and an effective S-1 registration statement.
Read More
